At WORLDSymposium, Astellas Pharma presented interim safety data from a Phase I/II study assessing the company’s AAV gene therapy for the rare, autosomal metabolic disease Pompe disease.

Vancouver, Wash.-based Absci Corporation inked a research pact with Merck. Absci will leverage the company’s Bionic Protein non-standard amino acid technology and its artificial intelligence-powered integrated Drug Creation Platform to create enzymes to meet Merck’s biomanufacturing applications.

Pfizer Inc. started dosing in a mid-to-late-stage trial of the company’s oral antiviral therapy for Covid-19 in non-hospitalized, symptomatic adult patients.

Australian scientists say they have developed the “holy grail” of blood sugar testing for diabetics, a non-invasive strip that checks glucose levels via saliva.

Intellia Therapeutics and Regeneron Pharmaceuticals shook the biotech and CRISPR world on June 26, announcing positive early data from the first-ever patients to have their DNA edited with an in vivo CRISPR/Cas9 therapy delivered systemically.

A study out of Washington University School of Medicine in St. Louis found that months after recovering from mild Covid-19, patients maintained antibodies against the SARS-CoV-2 virus. Researchers believe that the specific cells that produce the antibodies should persist for a lifetime.

Researchers from the Francis Crick Institute and the Latvian Institute of Organic Synthesis developed a new compound that blocks a step in the life cycle of the mosquito-borne parasite that causes malaria.

A judge in Hawaii ordered Bristol-Myers Squibb Co. and Sanofi SA to pay more than $834 million to the state for failing to warn non-white patients properly of health risks from the blood thinner Plavix.

Amicus Therapeutics announced topline results from the Phase III PROPEL pivotal trial of AT-GAA (cipaglucosidase alfa and miglustat) for late-onset Pompe disease.

Data with Sanofi’s investigational enzyme replacement therapy avalglucosidase alfa in late-onset Pompe disease and infantile-onset Pompe disease will be featured as platform and poster presentations at the 17th annual WORLDSymposiumTM, to be held February 8-12, 2021.